Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Acquisition

 This is to intimate you that Alkem Laboratories Limited (the 'Company') has entered into an asset purchase agreement dated 30th December, 2019 with AbbVie Inc., USA ('Agreement') for acquisition of certain assets as stated in Annexure I of this intimation letter related to the active pharmaceutical ingredient, Dronabinol ('Assets'). In this regard, the necessary disclosures/ information required to be submitted pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is enclosed as Annexure I. A copy of these disclosures will be made available on the Company's website as well in accordance with Regulation 30(8) of the SEBI Listing Regulations. Kindly take note of the same.
31-12-2019
Bigul

Alkem Laboratories Ltd - 539523 - Closure of Trading Window

 This is to inform you that in terms of Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window will remain closed from 30th December, 2019 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and nine months ended 31st December, 2019 are communicated to the Stock Exchanges.
23-12-2019
Bigul

Alkem Laboratories Ltd - 539523 - Disclosure Of Related Party Transactions On A Consolidated Basis Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed disclosures of related party transactions, on a consolidated basis, for the half year ended on 30th September, 2019 in the prescribed format. The same have been published on the website of the Company at www.alkemlabs.com. Kindly take the same on record.
29-11-2019
Bigul

Alkem Laboratories Ltd - 539523 - Closure of Trading Window

 We refer to our earlier communication dated 26th September, 2019 regarding closure of trading window (for the purpose of financial results for the quarter ended 30th September, 2019) starting from 28th September, 2019 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and half year ended 30th September, 2019 are communicated to the Stock Exchanges. The Financial Results of the Company for the quarter and half year ended 30th September, 2019 having been communicated to the Stock Exchanges, today i.e. 11th November, 2019, the trading window shall open on 14th November, 2019.
11-11-2019
Bigul

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Investor Presentation

 With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith press release and analyst presentation on Q2FY20 and H1FY20 earnings and business updates and the same will be uploaded on the website of the Company. Kindly take note of the same
11-11-2019
Bigul

Alkem Laboratories Ltd - 539523 - Results - Financial Results For September 30, 2019

 In continuation of our letter dated 18th October, 2019 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') the Board of Directors of the Company, at its meeting held today, i.e. 11th November, 2019, has inter alia: . 1. approved the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2019. Accordingly we are enclosing herewith the copy of Standalone and Consolidated Unaudited Financial Results along with the Limited Review Report of the Statutory Auditors of the Company for the quarter and half year ended 30th September, 2019, as required under Regulation 33 of the Listing Regulations. The meeting of the Board of Directors of the Company commenced at 10.30 A.M and concluded at 2.30 P.M Kindly take the same on record.
11-11-2019
Bigul

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Change in Directorate

 We wish to inform you that the board of directors ('Board') of Alkem Laboratories Limited (the 'Company'), at its meeting held today, i.e. on 11th November, 2019 has appointed Mr. Sarvesh Singh (DIN: 01278229) as an Additional Director and Whole Time Director designated as Executive Director on the Board for a period of five years, with effect from 11th November, 2019, subject to the approval of the shareholders of the Company at its ensuing annual general meeting. Necessary particulars in relation to the said appointment, are included in Annexure I. Kindly take the same on your records.
11-11-2019
Bigul

Alkem Laboratories Ltd - 539523 - Outcome of Board Meeting

 In continuation of our letter dated 18th October, 2019 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') the Board of Directors of the Company, at its meeting held today, i.e. 11th November, 2019, has inter alia: 1. approved the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2019. 2. appointed Mr. Sarvesh Singh (DIN: 01278229) as an Additional Director and as a Whole Time Director designated as Executive Director on the Board of Directors of the Company w.e.f 11th November, 2019. The meeting of the Board of Directors of the Company commenced at 10.30 A.M and concluded at 2.30 P.M
11-11-2019
Bigul

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Closure of US FDA Inspection at Alkem's manufacturing facilities located at Daman, India and Baddi, India.
01-11-2019
Bigul

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we write to inform you that a conference call to discuss the Q2FY20 and H1FY20 financial results will be held on Monday, 11th November, 2019 at 05.00 P.M. Please find attached herewith the conference call details. Kindly take note of the same.
23-10-2019
Next Page
Close

Let's Open Free Demat Account